Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
COYA Stock Chart & Stats
$4.20
-$0.10(-1.62%)
At close: 4:00 PM EST
$4.20
-$0.10(-1.62%)
Day’s Range― - ―
52-Week Range$3.94 - $7.75
Previous CloseN/A
Volume16.99K
Average Volume (3M)266.35K
Market Cap
$98.40M
Enterprise Value$23.35M
Total Cash (Recent Filing)$46.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.25
Next Earnings
May 07, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding23,457,184
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap0.24
Enterprise Value/Revenue2.94
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda-1.15
Forecast
1Y Price Target
$16.25Price Target Upside286.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$1.92M
Bulls Say, Bears Say
Bulls Say
Biomarker And Mechanistic SupportInvestigator-led data showing increased regulatory T-cell activity, combined with planned proteomics releases and top-line animal model results, provide biomarker-driven support for the immune-targeted mechanism of COYA 302.
Clinical AdvancementAdvancement across clinical programs, including completed enrollment in the lead ALS trial, initiation of a frontotemporal dementia study, and an announced double-blind phase two ALS trial with biomarker collection, creates multiple potential value inflection points for COYA 302.
Regulatory MilestoneFDA acceptance of an Investigational New Drug application for COYA 302 enables initiation of a U.S. clinical development program in frontotemporal dementia.
Bears Say
Clinical Development RiskALS programs have a high historical failure rate, so clinical setbacks or inability to advance COYA 302 into pivotal development would negatively affect the company's prospects.
Financing And Partnership RiskPartnership uncertainties and potential for equity dilution tied to financings or milestone structures could reduce shareholder value and weigh on the stock.
Limited Trial EvidenceSmall, single-center cohorts and short study durations in the frontotemporal dementia and investigator-initiated trials limit confidence in disease-modifying effects and make current results preliminary.
Coya Therapeutics, Inc. News
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $3.94 and its highest was $7.75 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Coya Therapeutics, Inc.’s market cap is $98.40M.
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 42 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on Mar 16, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.273 by -$0.067.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.42.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 23,457,184 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.273. Following the earnings report the stock price went down -0.662%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coya Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.25 (286.90% Upside)
$16.25 (286.90% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 17.5%
Last 30 Days ▲ 19.5%
Last 30 Days ▲ 19.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.31%
12-Months-Change
Fundamentals
Return on Equity
-62.18%
Trailing 12-Months
Asset Growth
-9.87%
Trailing 12-Months
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
COYA Stock 12 Month Forecast
Average Price Target
$16.25
▲(286.90% Upside)
Technical Analysis
Ownership Overview
4.42% Insiders
3.97% Mutual Funds
23.74% Other Institutional Investors
64.00% Public Companies and
Individual Investors